Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

38 trials with published results (12%)

Research Maturity

135 completed trials (43% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.4%

17 terminated out of 315 trials

Success Rate

88.8%

+2.3% vs benchmark

Late-Stage Pipeline

9%

28 trials in Phase 3/4

Results Transparency

28%

38 of 135 completed with results

Key Signals

38 with results89% success17 terminated

Data Visualizations

Phase Distribution

167Total
Not Applicable (128)
Early P 1 (3)
P 1 (1)
P 2 (7)
P 3 (8)
P 4 (20)

Trial Status

Completed135
Recruiting59
Unknown44
Not Yet Recruiting24
Terminated17
Active Not Recruiting14

Trial Success Rate

88.8%

Benchmark: 86.5%

Based on 135 completed trials

Clinical Trials (315)

Showing 20 of 20 trials
NCT06211296Not ApplicableCompleted

The ShortCut™ Continued Access Study Protocol

NCT04310046Not ApplicableActive Not RecruitingPrimary

Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial

NCT05035277Phase 3CompletedPrimary

AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation

NCT07620925RecruitingPrimary

Derivation and Validation of the Aortic Valve Echocardiographic Calcium Score to Confirm Severe Aortic Stenosis: the Echo-AVCS Study

NCT07623083Not Yet RecruitingPrimary

Evaluation of a Management Algorithm for TAVI Patients With Concomitant Mitral or Tricuspid Regurgitation

NCT06818006Phase 4Not Yet RecruitingPrimary

Application of TAVI at Experienced Interventional Cardiac Centers Without On-site Cardiac Surgery (ATLAS Study)

NCT06372301Not ApplicableCompleted

Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy

NCT05646381Phase 2RecruitingPrimary

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT07604402Not ApplicableRecruitingPrimary

TRanscatheter Aortic-Valve Implantation Without On-site Cardiac Surgery

NCT07614100Not ApplicableNot Yet RecruitingPrimary

Cerebral Microembolization During Transcatheter Aortic Valve Implantation: Comparing Balloon-expandable and Self-expanding Valves

NCT06777368RecruitingPrimary

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

NCT06713889RecruitingPrimary

Identifying Biological Markers of Cardiovascular Events in Patients With Aortic Stenosis or TAVI

NCT07605624Not Yet RecruitingPrimary

Active Post-Market Surveillance of Innovative Devices for Valvular Heart Disease

NCT02628509Completed

Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedure

NCT07276711Not ApplicableRecruiting

CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material

NCT07539259Phase 2Not Yet RecruitingPrimary

To Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes

NCT07479992RecruitingPrimary

Multicenter Study for the Validation of Willem AI: Aortic StenoSis Early Diagnosis With AI-electrocardiogram Study

NCT06749132Enrolling By InvitationPrimary

Deep Learning-enhanced Personalized Monitoring of Aortic Stenosis - The DETECT-AS Prognostic Study

NCT07450196Not Yet RecruitingPrimary

A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Valve Replacement for Type-0 Bicuspid Aortic Valve Stenosis Patients in China

NCT01757665Not ApplicableCompletedPrimary

ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)

Scroll to load more

Research Network

Activity Timeline